PMGC Holdings (ELAB) Accumulated Expenses (2023 - 2024)
PMGC Holdings (ELAB) posted Accumulated Expenses of $137567.0 for Q3 2024, up 237.12% sequentially from $40807.0 in Q2 2024.
PMGC Holdings (ELAB) Accumulated Expenses (2023 - 2024) Analysis & Trends
PMGC Holdings has reported Accumulated Expenses for 2 years, with the latest figure at $137567.0 in Q3 2024.
- Quarterly Accumulated Expenses changed N/A year-over-year to $137567.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $137567.0 (changed N/A YoY) and the FY2023 annual result came in at $73228.0, changed N/A from the prior year.
- Accumulated Expenses advanced to $137567.0 in Q3 2024 per ELAB's latest filing, from $40807.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $137567.0 in Q3 2024 and troughed at $40807.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 137,567.00 |
| Jun 30, 2024 | 40,807.00 |
| Mar 31, 2024 | 133,573.00 |
| Dec 31, 2023 | 73,228.00 |